What is Dianthus Therapeutics's stock issuance proceeds?

Dianthus Therapeutics (DNTH) reported stock issuance proceeds of $120K in Q1 2026.

How has Dianthus Therapeutics's stock issuance proceeds changed year-over-year?

Dianthus Therapeutics's stock issuance proceeds decreased by 7.0% year-over-year, from $129K to $120K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Dianthus Therapeutics DNTH Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Spyre Therapeutics, Inc.SYRE

$2.68M+1,128%

Kymera TherapeuticsKYMR

$19.19M—

Protagonist TherapeuticsPTGX

$23.37M+96.1%

TG TherapeuticsTGTX

$763K+3,533%

Immunovant, Inc.IMVT

$0-100%

Regeneron PharmaceuticalsREGN

$163.1M+169%

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's stock issuance proceeds?: Dianthus Therapeutics (DNTH) reported stock issuance proceeds of $120K in Q1 2026.
How has Dianthus Therapeutics's stock issuance proceeds changed year-over-year?: Dianthus Therapeutics's stock issuance proceeds decreased by 7.0% year-over-year, from $129K to $120K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.